Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 219, Issue 2, Pages 335-338Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiy514
Keywords
herpes zoster; zoster vaccine live; second dose; cell-mediated immunity
Categories
Funding
- Merck & Co., Inc., Kenilworth, NJ
Ask authors/readers for more resources
Protection against zoster conferred by zoster vaccine live (ZVL; Zostavax) wanes over time. We compared varicella-zoster virus cell-mediated immunity (VZV-CMI) of adults >= 70 years who received a second dose of ZVL >= 10 years after the initial dose with de novo-immunized age-matched controls. Before and during the first year after vaccination, VZV-CMI was significantly higher in reimmunized compared with de novo vaccinees. At 3 years, VZV-CMI differences between groups decreased and only memory responses remained marginally higher in reimmunized participants. In conclusion, the increase in VZV-CMI generated by reimmunization with ZVL is at least equally persistent compared with de novo immunization.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available